{"schema_version":"secwatch.filing_event.v1","accession":"0000914475-25-000006","form_type":"8-K","ticker":"NBIX","cik":"0000914475","company_name":"NEUROCRINE BIOSCIENCES INC","filed_at":"2025-01-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.787047+00:00","generated_at":"2026-05-27T09:55:29.364535+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Neurocrine restructures Takeda deal for osavampator; gets global rights ex-Japan","bullets":["Neurocrine obtains exclusive worldwide development/commercialisation rights for osavampator except Japan, converts from profit-sharing to royalty-bearing license.","Takeda reacquires exclusive rights in Japan; royalties payable by each party on net sales in other's territory.","Tiered royalties to Takeda: mid-to-upper teens (US), low double-digits (ex-US) as % of net sales.","Phase 3 program for major depressive disorder expected to start H1 2025 after successful End-of-Phase 2 FDA meeting.","Amended agreement dated January 24, 2025; press release issued January 27, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000914475-25-000006","json":"https://secwatch.observer/filing/0000914475-25-000006.json","markdown":"https://secwatch.observer/filing/0000914475-25-000006.md","text":"https://secwatch.observer/filing/0000914475-25-000006.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000006/0000914475-25-000006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000006/nbix-20250124.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T09:55:29.364535+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}